Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Loss of asthma control after cessation of omalizumab treatment: real life data Kuprys-Lipinska I; Kuna PPostepy Dermatol Alergol 2014[Feb]; 31 (1): 1-5INTRODUCTION: Many clinical and observational studies have demonstrated effectiveness of omalizumab (OMA) in the treatment of severe asthma, but the optimal duration of the therapy remains unknown. AIM: The article presents the authors' clinical experience on OMA cessation in routine practice. MATERIAL AND METHODS: Due to new reimbursement criteria, OMA therapy has been interrupted in 11 subjects (6 women/5 men). The mean age of patients was 50.73 +/-14.16 years, the mean time of severe asthma duration was 13.54 +/-6.05 years. All of them had an excellent/good response to OMA. The duration of OMA therapy was 67.73 +/-11.64 months. RESULTS: Nine out of 11 patients had severe asthma exacerbation within the first 5 months after the OMA withdrawal. The mean time to the first severe exacerbation was 7.56 +/-2.67 weeks. Between the time of OMA cessation and the time of reassessment, the mean score of Asthma Control Questionnaire increased from 2.58 +/-0.71 to 3.63 +/-1.26 points and the mean score of Asthma Quality of Life Questionnaire decreased from 4.3 +/-1.91 to 3.18 +/-1.17 points. The mean oral corticosteroids (OCS) dose increased from 4.61 +/-3.0 mg/day to 33.33 +/-13.12 mg/day. The number of exacerbations within the last 12 months increased from 1.6 +/-0.67 to 5.2 +/-1.4, and the number of hospitalizations or emergency room (ER) attendence increased from 0.11 +/-0.31 to 1.56 +/-1.26. CONCLUSIONS: These data indicate that the withdrawal of OMA therapy after the successful long-term therapy may cause severe asthma exacerbations. Therefore, the decision regarding cessation of OMA treatment should be undertaken individually after careful weighing benefits and risks, especially in patients with a long history of severe asthma, treated with high doses of OCS before OMA introduction, near-fatal asthma events and/or aggravation of asthma during previous episodes of interruptions in OMA treatment.ä |
